ROIV
Roivant Sciences Ltd. Common Shares
Nasdaq · usd
Roivant Sciences Ltd. Common Shares (ROIV) trades at $36.07 (-1.14%) as of 2:05:09 PM EDT on Oct 26, 2026, +0.59% over the past month. Market cap is $26.36B, with 4.4 days to cover in short interest.
Stock performance
How Roivant Sciences Ltd. Common Shares (ROIV) stock has performed from one day to one year, with its 52-week range.
- 1D
- -1.32%
- 1W
- +3.78%
- 1M
- +0.59%
- YTD
- +65.94%
- 1Y
- +91.44%
- 52-wk range
- $18.27 – $42.50
Key statistics
Today's trading snapshot for ROIV: day range, open, previous close, volume and market cap.
- Day range
- $35.85 – $36.91
- Open
- $36.66
- Prev close
- $36.49
- Volume
- 4.15M
- Market cap
- $26.36B
- Shares out
- 722.32M
Valuation and profitability ratios: P/E, P/S, ROE
Valuation and profitability ratios for Roivant Sciences Ltd. Common Shares: P/E, P/S, P/B, ROE and more.
- P/E
- —
- P/S
- 3499.41
- P/B
- 6.23
- P/FCF
- —
- ROE
- -6.3%
- ROA
- -5.0%
- Debt/Equity
- 0.00
- Div yield
- 0.00%
As of Oct 23, 2026
8-K filings
Material corporate events Roivant Sciences Ltd. Common Shares has disclosed to the SEC on Form 8-K.
- Clinical trial resultsOct 21, 2026
On October 21, 2026, Roivant Sciences Ltd. issued a press release announcing positive results from the Phase 3 CLARITY program evaluating brepocitinib in non-infectious uveitis (NIU) conducted by its subsidiary, Priovant Therapeutics, Inc.
- Annual meeting resultsSep 18, 2026
On September 16, 2026, Roivant Sciences Ltd. held its 2026 Annual General Meeting of Shareholders. ... All proposals on the agenda were approved by the shareholders. Below are the final voting results.
- Clinical trial resultsSep 8, 2026
On September 8, 2026, Roivant Sciences Ltd. (the "Company") issued a press release announcing positive results from the PHocus clinical trial evaluating mosliciguat for the treatment of pulmonary hypertension associated with interstitial lung disease conducted by its subsidiary, Pulmovant, Inc.
- Product or service launchAug 28, 2026
The approval by the U.S. Food and Drug Administration of LISRAYA™ (brepocitinib) for the treatment of adults with dermatomyositis represents a significant new product launch. The wholesale acquisition cost of LISRAYA is $35,000 for a 30-count bottle of 30 mg tablets.
- Regulatory decisionAug 27, 2026
the U.S. Food and Drug Administration had approved the New Drug Application for LISRAYA™ (brepocitinib) for the treatment of adults with dermatomyositis submitted by the Company's subsidiary, Priovant Therapeutics, Inc.
ROIV short interest
How heavily ROIV is shorted: shares short, days to cover and average daily volume.
- Days to cover
- 4.4
- Short interest
- 39.3M
- Avg volume
- 8.88M
As of · reported to FINRA twice monthly.
ROIV news
The latest news and headlines about Roivant Sciences Ltd. Common Shares (ROIV).
- Immunovant to Report Financial Results for the Second Fiscal Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026neutralGlobeNewswire Inc.· Oct 21, 2026
- Roivant and Priovant Announce Positive Results in CLARITY-1 and CLARITY-2 Phase 3 Trials for Brepocitinib in Non-Infectious Uveitis (NIU)positiveGlobeNewswire Inc.· Oct 21, 2026
- Company News for Sep 9, 2026positiveZacks Investment Research· Sep 9, 2026
- Dr. Gillian Cannon Joins Lindus Therapeutics’ Board as a Non-Executive DirectorneutralGlobeNewswire Inc.· Sep 8, 2026
- Myasthenia Gravis Market Set to Surpass USD 16 Billion by 2036, Fueled by Rising Diagnosed Prevalence and Wave of Targeted Biologic Approvals | DelveInsightpositiveGlobeNewswire Inc.· May 18, 2026
Frequently asked questions
What is the Roivant Sciences Ltd. Common Shares (ROIV) stock price today?
Roivant Sciences Ltd. Common Shares (ROIV) is trading at $36.07 (-1.14% on the day) as of 2:05:09 PM EDT on Oct 26, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.
What is Roivant Sciences Ltd. Common Shares?
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business.
What is the short interest in ROIV?
As of Sep 30, 2026, ROIV has 39.3M shares short and 4.4 days to cover.
What exchange is ROIV listed on?
Roivant Sciences Ltd. Common Shares (ROIV) trades on Nasdaq in USD, in the PHARMACEUTICAL PREPARATIONS industry.
Build with AI
Build an analysis of ROIV with your agent
Point Claude or ChatGPT at the Massive MCP server and recreate this page from live data.
Connect the Massive MCP server (API reference: massive.com/docs/llms.txt) and build a ROIV analysis: the latest quote, key ratios (P/E, P/S, ROE), short interest, recent insider activity and the latest news.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.